Is Qualigen Therapeutics, Inc. (QLGN) a Buy, Sell, or Hold?
NASDAQ : QLGN
Qualigen Therapeutics, Inc.
$3.21 USD
$0.17 (5.59%)
- Volume
- 368.77K
- Average Volume
- 2.65M
- Market Capitalization
- $5.43M
- P/E Ratio
- -0.51
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.81
- Year Low
- $1.61
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$0.07
- Current Ratio
- $3.68
Company Overview
NASDAQ
Kevin A. Richardson II
Biotechnology
Healthcare
QLGN
4
US
USD
Liquidity Metrics
0.00
3.68
3.68
0.34
-0.07
Sales & Valuation
-$
0.00
11.46
-0.45
-0.60
Profitability
-$8.11
-$19.53M
0.00%
0.00%
-108.30%
-343.97%
P/E Metrics
-0.51
0.01
0.01
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-33.02
2/9
$4.62M
$7.4M
$1.72M
-$16.24M
Key Metrics (TTM)
$4.85M
0.00
-0.30
3.68
-108.30%
-283.13%
-39.10%
-224.72%
0 days
Company Executives
| Name | Title |
|---|---|
| Christopher L. Lotz | Vice President of Finance & Corporate Secretary |
| Robert W. Campbell Becher | President |
| Kevin A. Richardson | Co-Chief Executive Officer, Chief Accounting Officer & Chairman of the Board |
| Michael S. Poirier | Chief Operating Officer |
| Jiawei Wang | Co-Chief Executive Officer |
| Koti Meka | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Stock
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a p ... atient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Frequently Asked Questions
-
What is the current Qualigen Therapeutics, Inc. (QLGN) stock price?
-
Qualigen Therapeutics, Inc.(NASDAQ:QLGN) stock price is $3.21 in the last trading session. During the trading session, QLGN stock reached the peak price of $8.81 while $1.61 was the lowest point it dropped to. The percentage change in QLGN stock occurred in the recent session was 5.59% while the dollar amount for the price change in QLGN stock was $0.17.
-
QLGN's industry and sector of operation?
-
The NASDAQ listed QLGN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of QLGN?
-
Christopher L. Lotz | Vice President of Finance & Corporate Secretary
Robert W. Campbell Becher | President
Kevin A. Richardson | Co-Chief Executive Officer, Chief Accounting Officer & Chairman of the Board
Michael S. Poirier | Chief Operating Officer
Jiawei Wang | Co-Chief Executive Officer -
How many employees does QLGN have?
-
Number of QLGN employees currently stands at 4. QLGN operates from 2042 Corte Del Nogal, Carlsbad, CA 92011, US.
-
Link for QLGN official website?
-
Official Website of QLGN is: https://qlgntx.com
-
How do I contact QLGN?
-
QLGN could be contacted at phone #760 918 9165 and can also be accessed through its website. QLGN operates from 2042 Corte Del Nogal, Carlsbad, CA 92011, US.
-
How many shares of QLGN are traded daily?
-
The average number of QLGN shares traded daily for last 3 months was 2.65M.
-
What is the market cap of QLGN currently?
-
The market value of QLGN currently stands at $5.43M with its latest stock price at $3.21